AFFX : Analysis & Opinions

  1. Affymetrix Hits 52-Week High on Strong Top-Line Growth - Analyst ...

    January 21, 2015
    Shares of Affymetrix Inc. (AFFX) scaled a new 52-week high of $11.89 on Jan 20, eventually closing at $11.65.
  2. Amgen (AMGN) Reveals Mixed Results from Vectibix Studies - Analyst ...

    January 16, 2015
    Amgen (AMGN) announced new data from the phase II PEAK study and the phase III PRIME study on Vectibix.
  3. Illumina Unveils 3 NGS Systems, Modifies Business Strategy - ...

    January 16, 2015
    llumina's (ILMN) NextSeq 550 System is the first next generation sequencer that allows array scanning.
  4. Illumina Declares Impressive Q4, 2014 Preliminary Results - Analyst ...

    January 15, 2015
    Illumina (ILMN) estimates total revenue of $512 million for the yet to-be-reported fourth quarter, which reflects a massive ...
  5. Qiagen Up on CE-IVD Mark for New Liquid Biopsy Test Kit - Analyst ...

    January 15, 2015
    Qiagen (QGEN) currently offers the therascreen EGFR test as a tissue-based companion diagnostic for lung cancer patients ...
  6. Fluidigm's Preliminary Q4 Revenues Up Y/Y, Outlook Positive - ...

    January 14, 2015
    Fluidigm Corp (FLDM) recently announced its preliminary fourth-quarter 2014 revenues.
  7. Amgen Maintains 2015 View, Expects Several Drug Launches - Analyst ...

    January 14, 2015
    Amgen (AMGN) said that it is maintaining its 2015 revenue guidance.
  8. Qiagen Up on Enzymatics' Unit Buy, ArcherDX Partnership Deal ...

    January 14, 2015
    Qiagen (QGEN) expects this buyout to provide approximately $20 million CER (constant exchange rates) of incremental net sales
  9. Celgene's Preliminary Results & 2015 Outlook Encouraging - Analyst ...

    January 13, 2015
    Celgene Corporation (CELG) provided encouraging guidance for 2015.
  10. Illumina Partners Lockheed Martin for Genomics Solutions - Analyst ...

    January 13, 2015
    Illumina Inc. (ILMN) recently formed a strategic alliance with Lockheed Martin (LMT).
  11. Perrigo/Ferrara Candy Ink Supply Deal for Gummy Products - Analyst ...

    January 13, 2015
    The Nutritionals unit at Perrigo Company (PRGO) has inked a five-year supply agreement with Ferrara Candy Company.
  12. Affymetrix's Preliminary Q4 Revenues Outshine Estimates - Analyst ...

    January 13, 2015
    Affymetrix Inc (AFFX) recently announced preliminary revenue expectation for the fourth quarter of 2014.
  13. Will Qiagen's Qiasymphony Placements Weave Magic in 2015? - Analyst ...

    January 13, 2015
    Qiagen's (QGEN) QIAsymphony automation solution refers to a revolutionizing molecular testing workflow which offers flexible ...
  14. Conatus Announced Results from Emricasan Studies - Analyst Blog

    January 12, 2015
    Conatus (CNAT) announced top-line results from studies on emricasan in organ-impaired patients.
  15. AMAG Provides 2014 Preliminary Results & 2015 Guidance - Analyst ...

    January 12, 2015
    AMAG Pharmaceuticals (AMAG) provided preliminary results for the fourth quarter and full year 2014 as well as its 2015 financial ...
  16. Qiagen (QGEN) Launches Next-Gen TB Infection Test - Analyst Blog

    January 12, 2015
    Qiagen's (QGEN) QFT-Plus is the fourth generation of the most accurate test used in the diagnosis of tuberculosis (TB) infection.
  17. Myriad's Tumor-Based Cancer Test Wins CE Mark, Shares Up - Analyst ...

    January 12, 2015
    Myriad Genetic's (MYGN) Tumor BracAnalysis CDx has become the first ever tumor-based companion diagnostic test to receive ...
  18. Affymetrix (AFFX) Expands Genotyping Arrays Product Line - Analyst ...

    January 12, 2015
    Provider of life science tools and molecular diagnostic products, Affymetrix, Inc. (AFFX), is expected to highlight various ...
  19. Arena Pharmaceuticals Soars on Positive Study Results - Analyst ...

    January 8, 2015
    Arena Pharmaceuticals' (ARNA) shares skyrocketed after announcing encouraging results from a phase Ib study on APD334.
  20. Alexion Reports Disappointing Phase II Data on Soliris - Analyst ...

    January 8, 2015
    Alexion Pharmaceuticals, Inc. reported disappointing data from a phase II study evaluating Soliris for the prevention of ...
  21. Biodel Posts Positive Preliminary Data on its Diabetes Drug - ...

    January 8, 2015
    Biodel Inc. (BIOD) announced positive preliminary data from a phase IIa study on its diabetes candidate, BIOD-531.
  22. Gilead to Purchase Liver Disease Program from Phenex - Analyst ...

    January 7, 2015
    Gilead Sciences, Inc. announced that it has entered into an agreement with Phenex Pharmaceuticals.
  23. Celsion Submits Study Protocol for Oncology Candidate - Analyst ...

    January 7, 2015
    Celsion Corporation (CLSN) announced that it has submitted a phase I study protocol for GEN-1 to the FDA.
  24. Salix CEO to Step Down, Inventory Issues Remain in Focus - Analyst ...

    January 6, 2015
    Salix Pharmaceuticals' (SLXP) President and CEO, Carolyn Logan, has decided to step down from its position by the end of ...
  25. Aquinox Starts Dosing for an Atopic Dermatitis Study - Analyst ...

    January 5, 2015
    Aquinox (AQXP) has started dosing in the phase II KINSHIP study on its atopic dermatitis candidate, AQX-1125.
  26. Idera Gets Orphan Drug Status for its Oncology Candidate - Analyst ...

    December 31, 2014
    Idera Pharmaceuticals (IDRA) announced that the FDA has granted orphan drug designation to IMO-8400.
  27. Hospira's Dyloject Cleared in the U.S. for Pain Management - ...

    December 31, 2014
    The FDA has approved Hospira's (HSP) proprietary nonsteroidal anti-inflammatory drug analgesic, Dyloject.
  28. Alexion Seeks FDA Approval for its Hypophosphatasia Drug - Analyst ...

    December 31, 2014
    Alexion Pharmaceuticals is looking to get asfotase alfa approved in the U.S. for treating patients suffering from hypophosphatasia.
  29. Cyberonics: VNS Therapy Strong, Reimbursement Woes Stay - Analyst ...

    December 30, 2014
    On Dec 29, we issued an updated research report on Cyberonics Inc. (CYBX).
  30. Qiagen Poised on Molecular Diagnostics, International Strength ...

    December 30, 2014
    On Dec 30, we issued an updated research report on Qiagen N.V. (QGEN).
  31. Fluidigm's Single-Cell Workflow to Advance Cancer Research - ...

    December 30, 2014
    The new application by Fluidigm Corp. (FLDM) will empower cancer researchers to predict cancer susceptibility, metastasis ...
  32. Can-Fite Enrols First Patient for a Liver Cancer Study - Analyst ...

    December 29, 2014
    Can-Fite (CANF) announced that it started dosing patients for a phase II study on CF 102.
  33. Affymetrix (AFFX) Touches 52-Week High on Bullish Trends - Analyst ...

    December 29, 2014
    Shares of Affymetrix Inc. (AFFX) scaled a 52-week high of $10.14 on Dec 26 and closed at $10.07, representing a healthy year-to-date ...
  34. Cytokinetics Rises After Extending Astellas Agreement - Analyst ...

    December 24, 2014
    Cytokinetics (CYTK) shares jumped after announcing an amendment to its collaboration with Astellas.
  35. Myriad Genetics' Ovarian Cancer Test Wins FDA Approval - Analyst ...

    December 24, 2014
    Myriad Genetics' (MYGN) BracAnalysis CDx has become the first and only FDA-approved test to be permitted for use with AstraZeneca's ...
  36. Stryker & Osiris Team Up to Market Viable Bone Matrix - Analyst ...

    December 23, 2014
    Under the partnership, Stryker Corporation (SYK) will attain exclusive, worldwide rights to Osiris' viable bone matrix under ...
  37. Will myRisk Cancer Test Work Wonders for Myriad Genetics? - Analyst ...

    December 23, 2014
    During the reported quarter,Myriad Genetics (MYGN) experienced heightened physician demand for the myRisk test.
  38. Walgreens Beats Q1 Earnings, Alliance Boots Deal Bears Fruit ...

    December 23, 2014
    Walgreens reported an impressive first quarter fiscal 2015 with both the top and bottom line comfortably beating the Zacks ...
  39. Explosive Stocks Under $10 - Screen of the Week

    December 22, 2014
    Explosive Stocks Under $10 - Screen of the Week
  40. Genomic Health (GHDX) Shines on Prospective Cancer Tests - Analyst ...

    December 22, 2014
    Genomic Health (GHDX) strongly believes that its Oncotype DX prostate cancer test will strengthen its advanced next generation ...
  41. Integra Lifesciences Up on Launch of Bilayer Skin Product - ...

    December 19, 2014
    This latest single-use skin product of Integra (IART) is at present the only pre-meshed bilayer matrix that has been approved ...
  42. Bruker Unveils bioAFM System for High Resolution Imaging - Analyst ...

    December 18, 2014
    Bruker's (BRKR) BioScope Resolve provides real-time correlation of atomic force microscopy and optical microscopy data sets
  43. Is Illumina (ILMN) Worth Adding to Your Portfolio? - Analyst ...

    December 16, 2014
    On Dec 10, 2014, we issued an updated research report on Illumina Inc. (ILMN).
  44. Genomic Health's Breast Cancer Test Yields Positive Results - ...

    December 16, 2014
    Oncotype DX breast cancer test ??? as Genomic Health's (GHDX) first product ??? has been an important contributor to U.S. ...
  45. Jazz Pharmaceuticals Starts Defibrotide Rolling NDA Filing - ...

    December 15, 2014
    Jazz Pharmaceuticals (JAZZ) has started the rolling submission of a NDA for defibrotide.
  46. Bull of the Day: Affymetrix (AFFX) - Bull of the Day

    November 5, 2014
    Bull of the Day: Affymetrix (AFFX) - Bull of the Day
  47. Bull of the Day: Affymetrix (AFFX) - Bull of the Day

    June 25, 2014
    Bull of the Day: Affymetrix (AFFX) - Bull of the Day
  48. Bull of the Day: Affymetrix (AFFX) - Bull of the Day

    January 10, 2014
    Bull of the Day: Affymetrix (AFFX) - Bull of the Day
  49. R&D The Future For Life Sciences Equipment Firms

    September 20, 2011
    Finding new healthcare solutions will be a paramount concern going forward. For investors, the best way to profit from this ...
  50. Affymetrix's Downward Spiral Continues

    July 7, 2011
    Affymetrix continues to flounder with unexciting technology.
  51. Illumina Lights Up Again

    April 29, 2011
    Illumina is a torrid grower, and growth investors seem to be willing to pay any price.
  52. Big Pharma's Big Problem

    August 16, 2010
    Big Pharma's best patents are expiring, but it may be able to reinvent itself through acquisitions.
  53. Affymetrix Misses Revenue Again And Again

    October 16, 2008
    Affymetrix missed revenue for the third consecutive quarter and blamed weak sales on a weak market - something competitors ...
Trading Center